pharmaceutical industry

Drug makers often sign CDMO renewals before they know when generics arrive

Entresto sales fell 43% after US generic entry in 2025. Fixed CDMO batch minimums don't shrink when generics arrive. The sponsor still owes them.

Crown Bioscience Appoints Guy Sheets as Senior Vice President, Commercial

Crown Bioscience has named Guy Sheets, a 30-year pharma and life sciences veteran, as its new senior vice president of commercial.

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Eli Lilly are expanding their strategic partnership, which began in 2023, with a series of substantial investments aimed at bolstering U.S. pharmaceutical manufacturing. The collaboration, marked by a $750 million investment, focuses on increasing the production of Lilly’s KwikPen®, a

Samsung Biologics reports $262M manufacturing deal running through 2033

Samsung Biologics disclosed a $262 million manufacturing deal with an undisclosed European pharmaceutical company that runs through 2033.

Biopharma's $300 Billion Patent Cliff Is Driving Its Strongest M&A Cycle Since the Pre-Pandemic Peak

More than $300 billion in branded pharmaceutical revenue faces patent expiration by 2030. Big Pharma cannot replace it through internal R&D alone. The result is the most aggressive acquisition cycle since before the pandemic, and it is reshaping how the entire life sciences supply chain does business.

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences initiates what it calls the first Phase I trial of an AI-designed oral drug formulation, approved by the UK's MHRA.